L. Schneider

发表

Adherence to and Effectiveness of Highly Active Antiretroviral Treatment for HIV Infection: Assessing the Bidirectional Relationship

J. Moatti, K. Lamiraud, F. Raffi, 2012, Medical care.

Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient

L. Schneider, H. Izzedine, P. Bossi, 2008, NDT plus.

Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients

G. Carcelain, A. Samri, C. Katlama, 2010, AIDS.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy

R. Tubiana, C. Katlama, L. Schneider, 2012, Antiviral therapy.

HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.

G. Carcelain, C. Katlama, B. Autran, 2011, Blood.

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

R. Tubiana, C. Katlama, D. Costagliola, 2022, European Journal of Clinical Microbiology & Infectious Diseases.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.

V. Calvez, R. Tubiana, C. Katlama, 2009, The Journal of antimicrobial chemotherapy.

Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs

V. Calvez, R. Tubiana, C. Delaugerre, 2003, Journal of Clinical Microbiology.

Switching to darunavir/ritonavir 800/100 mg once‐daily containing regimen maintains virological control in fully suppressed pre‐treated patients infected with HIV‐1

C. Katlama, L. Schneider, R. Murphy, 2013, Journal of medical virology.

Dual therapy with lamivudine + protease inhibitor during pregnancy for prevention of mother-to-child transmission of HIV-1.

R. Tubiana, C. Katlama, L. Schneider, 2013, Journal of acquired immune deficiency syndromes.

Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients

C. Katlama, B. Autran, V. Appay, 2011, AIDS.

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.

G. Carcelain, R. Tubiana, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

C. Katlama, M. Duracinsky, D. Costagliola, 2018, The Journal of antimicrobial chemotherapy.

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

V. Calvez, C. Katlama, L. Schneider, 2003, AIDS.

Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals

V. Calvez, C. Katlama, D. Costagliola, 2002, Antiviral therapy.

Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men

V. Calvez, C. Katlama, L. Schneider, 2021, Open forum infectious diseases.

Poppers by inducing HHV-8 virion production can act as a promoter for HHV-8 transmission in MSM

V. Calvez, C. Katlama, L. Schneider, 2021 .

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies.

V. Calvez, R. Tubiana, C. Katlama, 2013, The Journal of antimicrobial chemotherapy.

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

R. Tubiana, C. Katlama, L. Cuzin, 2022, Journal of acquired immune deficiency syndromes.

Bariatric surgery in HIV patients: experience of an Obesity Reference Center in France.

L. Schneider, G. Peytavin, S. Gallien, 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

Vincent Calvez, Christine Katlama, V. Calvez, 2005, AIDS.

Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy

V. Calvez, C. Delaugerre, C. Katlama, 2004, Antimicrobial Agents and Chemotherapy.

Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of infectious diseases.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

V. Calvez, C. Katlama, D. Costagliola, 2015, The Journal of antimicrobial chemotherapy.

Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris

R. Tubiana, C. Katlama, L. Schneider, 2023, Sexually Transmitted Infections.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

V. Calvez, C. Katlama, L. Schneider, 2009, AIDS.

More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy.

V. Calvez, R. Tubiana, C. Katlama, 2022, The Journal of antimicrobial chemotherapy.

Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.

V. Calvez, R. Tubiana, C. Katlama, 2014, The Journal of antimicrobial chemotherapy.

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV

R. Tubiana, C. Katlama, L. Schneider, 2023, Journal of personalized medicine.

Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.

G. Carcelain, C. Katlama, B. Autran, 2011, Blood.

High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France

C. Katlama, L. Schneider, R. Palich, 2023, Sexually Transmitted Infections.

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial

C. Katlama, Y. Yazdanpanah, F. Raffi, 2021, AIDS Research and Therapy.